» Articles » PMID: 34995355

Conditioning Intensity and Peritransplant Flow Cytometric MRD Dynamics in Adult AML

Abstract

In acute myeloid leukemia (AML), measurable residual disease (MRD) before or after allogeneic hematopoietic cell transplantation (HCT) is an established independent indicator of poor outcome. To address how peri-HCT MRD dynamics could refine risk assessment across different conditioning intensities, we analyzed 810 adults transplanted in first or second remission after myeloablative conditioning (MAC; n = 515) or non-MAC (n = 295) who underwent multiparameter flow cytometry-based MRD testing before as well as 20 to 40 days after allografting. Patients without pre- and post-HCT MRD (MRDneg/MRDneg) had the lowest risks of relapse and highest relapse-free survival (RFS) and overall survival (OS). Relative to those patients, outcomes for MRDpos/MRDpos and MRDneg/MRDpos patients were poor regardless of conditioning intensity. Outcomes for MRDpos/MRDneg patients were intermediate. Among 161 patients with MRD before HCT, MRD was cleared more commonly with a MAC (85 of 104; 81.7%) than non-MAC (33 of 57; 57.9%) regimen (P = .002). Although non-MAC regimens were less likely to clear MRD, if they did, the impact on outcome was greater. Thus, there was a significant interaction between conditioning intensity and "MRD conversion" for relapse (P = .020), RFS (P = .002), and OS (P = .001). Similar findings were obtained in the subset of 590 patients receiving HLA-matched allografts. C-statistic values were higher (indicating higher predictive accuracy) for peri-HCT MRD dynamics compared with the isolated use of pre-HCT MRD status or post-HCT MRD status for prediction of relapse, RFS, and OS. Across conditioning intensities, peri-HCT MRD dynamics improve risk assessment over isolated pre- or post-HCT MRD assessments in patients with AML.

Citing Articles

Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given.

Rodriguez-Arboli E, Phillips G, Pardee T, Lazarus H, Gale R Leukemia. 2025; .

PMID: 40074851 DOI: 10.1038/s41375-025-02560-3.


Impact of high-sensitivity flow cytometry on peri-transplant minimal residual disease kinetics in acute leukemia.

de Azambuja A, Beltrame M, Malvezzi M, Schluga Y, Justus J, Lima A Sci Rep. 2025; 15(1):6942.

PMID: 40011589 PMC: 11865467. DOI: 10.1038/s41598-025-91936-7.


Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.

Gang M, Othus M, Walter R Cells. 2025; 14(4).

PMID: 39996762 PMC: 11853423. DOI: 10.3390/cells14040290.


Modulators of relapse risk in adults allografted for acute myeloid leukemia in measurable residual disease-positive remission.

Gang M, Othus M, Sandmaier B, Davis C, Basom R, Walter R Bone Marrow Transplant. 2025; .

PMID: 39962220 DOI: 10.1038/s41409-025-02533-1.


Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML.

Vo P, Sandmaier B, Othus M, Ali N, Rodriguez-Arboli E, Orvain C Bone Marrow Transplant. 2025; .

PMID: 39881206 DOI: 10.1038/s41409-025-02516-2.


References
1.
Hourigan C, Gale R, Gormley N, Ossenkoppele G, Walter R . Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017; 31(7):1482-1490. DOI: 10.1038/leu.2017.113. View

2.
Heuser M, Freeman S, Ossenkoppele G, Buccisano F, Hourigan C, Ngai L . 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021; 138(26):2753-2767. PMC: 8718623. DOI: 10.1182/blood.2021013626. View

3.
Walter R, Ofran Y, Wierzbowska A, Ravandi F, Hourigan C, Ngai L . Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. Leukemia. 2021; 35(6):1529-1538. DOI: 10.1038/s41375-021-01230-4. View

4.
Wood B . Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach. Curr Protoc Cytom. 2020; 93(1):e73. DOI: 10.1002/cpcy.73. View

5.
Walter R, Gyurkocza B, Storer B, Godwin C, Pagel J, Buckley S . Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2014; 29(1):137-44. PMC: 4254901. DOI: 10.1038/leu.2014.173. View